+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-infectives Market by Product, Pathogen, Mechanism Of Action, Route Of Administration, End User - Global Forecast 2025-2030- Product Image
Anti-infectives Market by Product, Pathogen, Mechanism Of Action, Route Of Administration, End User - Global Forecast 2025-2030- Product Image
Sale

Anti-infectives Market by Product, Pathogen, Mechanism Of Action, Route Of Administration, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6015081
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-infectives Market grew from USD 125.78 billion in 2023 to USD 131.43 billion in 2024. It is expected to continue growing at a CAGR of 5.12%, reaching USD 178.43 billion by 2030.

Anti-infectives encompass drugs and medications designed to combat infections by inhibiting the growth of or eliminating the microbes causing disease, such as bacteria, viruses, fungi, and parasites. The necessity for anti-infectives is underscored by the continuous emergence and re-emergence of infectious diseases and the rising threat of antibiotic-resistant strains, necessitating robust research and development in this field. These pharmaceuticals find application across various settings, including hospitals, outpatient care, and personal home use, targeting infections ranging from common bacterial to complex viral types. The end-users range from individual consumers and healthcare providers to entire healthcare facilities and governmental bodies, emphasizing a broad market penetration. Key factors influencing market growth include the increasing prevalence of chronic diseases leading to a higher risk of secondary infections, advancements in biotechnology resulting in new drug formulations, and supportive government initiatives promoting the development of novel anti-infectives. Opportunities abound with the burgeoning demand for targeted therapies and personalized medicine, encouraging more focused research on narrow-spectrum antibiotics and anti-viral agents. Businesses can thrive by leveraging strategic partnerships and prioritizing research in novel antibiotics, peptides, and phage therapies. However, limitations include stringent regulatory requirements, high costs associated with drug development, and the relatively slow pace of introduction of new products to the market due to extensive testing phases. Challenges like the adaptive nature of pathogens leading to resistance and market saturation with generic drugs further complicate market dynamics. Innovations could focus on developing rapid diagnostic tools, improving drug efficacy, and enhancing delivery systems, such as nanoparticle-based carriers, to ensure targeted action with minimal side effects. Overall, the anti-infectives market remains robust, yet complex, requiring constant adaptation and innovation to meet evolving healthcare needs and combat resistance trends effectively.

Understanding Market Dynamics in the Anti-infectives Market

The Anti-infectives Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Expansion of healthcare infrastructure in emerging economies fueling the anti-infectives market growth
    • Stringent regulatory guidelines promoting the development and approval of effective anti-infective medications
    • The pharmaceutical industry's strategic collaborations and partnerships to boost anti-infective drug discovery
    • Increasing healthcare expenditure and better access to medical facilities driving demand for anti-infectives
  • Market Restraints
    • Lower return on investment due to short product lifecycles and high cost of development in anti-infective market
    • Patient non-adherence to prescribed anti-infective regimens leading to suboptimal treatment outcomes and increased resistance
  • Market Opportunities
    • Growth of personalized medicine approaches for targeted anti-infective treatments based on patient-specific factors
    • Leveraging artificial intelligence and machine learning for rapid identification of novel anti-infective compounds
    • Investing in advanced biotechnological research for development of next-generation anti-microbial therapies
  • Market Challenges
    • Escalating research and development costs limiting innovation and new drug discoveries in anti-infectives
    • High market entry barriers preventing small and medium-sized enterprises from competing effectively

Exploring Porter’s Five Forces for the Anti-infectives Market

Porter’s Five Forces framework further strengthens the insights of the Anti-infectives Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Anti-infectives Market

External macro-environmental factors deeply influence the performance of the Anti-infectives Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Anti-infectives Market

The Anti-infectives Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Anti-infectives Market

The Anti-infectives Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Anti-infectives Market

The Anti-infectives Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-infectives Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Shionogi & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Anti-infectives Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product
    • Biologics
      • Interferons
      • Monoclonal Antibodies
      • Recombinant Proteins
    • Drugs
      • Intravenous
      • Oral Liquids
      • Tablets
    • Vaccines
      • Bacterial Vaccines
      • Viral Vaccines
  • Pathogen
    • Bacterial Infections
      • Escherichia Coli
      • Staphylococcus Aureus
    • Fungal Infections
      • Aspergillus
      • Candida
    • Parasitic Infections
      • Leishmaniasis
      • Malaria
    • Viral Infections
      • Hepatitis
      • HIV
  • Mechanism Of Action
    • Cell Wall Synthesis Inhibitors
    • Nucleic Acid Synthesis Inhibitors
    • Protein Synthesis Inhibitors
  • Route Of Administration
    • Intravenous
    • Oral
    • Topical
  • End User
    • Clinics
    • Homecare
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Expansion of healthcare infrastructure in emerging economies fueling the anti-infectives market growth
5.1.1.2. Stringent regulatory guidelines promoting the development and approval of effective anti-infective medications
5.1.1.3. The pharmaceutical industry's strategic collaborations and partnerships to boost anti-infective drug discovery
5.1.1.4. Increasing healthcare expenditure and better access to medical facilities driving demand for anti-infectives
5.1.2. Restraints
5.1.2.1. Lower return on investment due to short product lifecycles and high cost of development in anti-infective market
5.1.2.2. Patient non-adherence to prescribed anti-infective regimens leading to suboptimal treatment outcomes and increased resistance
5.1.3. Opportunities
5.1.3.1. Growth of personalized medicine approaches for targeted anti-infective treatments based on patient-specific factors
5.1.3.2. Leveraging artificial intelligence and machine learning for rapid identification of novel anti-infective compounds
5.1.3.3. Investing in advanced biotechnological research for development of next-generation anti-microbial therapies
5.1.4. Challenges
5.1.4.1. Escalating research and development costs limiting innovation and new drug discoveries in anti-infectives
5.1.4.2. High market entry barriers preventing small and medium-sized enterprises from competing effectively
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Anti-infectives Market, by Product
6.1. Introduction
6.2. Biologics
6.2.1. Interferons
6.2.2. Monoclonal Antibodies
6.2.3. Recombinant Proteins
6.3. Drugs
6.3.1. Intravenous
6.3.2. Oral Liquids
6.3.3. Tablets
6.4. Vaccines
6.4.1. Bacterial Vaccines
6.4.2. Viral Vaccines
7. Anti-infectives Market, by Pathogen
7.1. Introduction
7.2. Bacterial Infections
7.2.1. Escherichia Coli
7.2.2. Staphylococcus Aureus
7.3. Fungal Infections
7.3.1. Aspergillus
7.3.2. Candida
7.4. Parasitic Infections
7.4.1. Leishmaniasis
7.4.2. Malaria
7.5. Viral Infections
7.5.1. Hepatitis
7.5.2. HIV
8. Anti-infectives Market, by Mechanism Of Action
8.1. Introduction
8.2. Cell Wall Synthesis Inhibitors
8.3. Nucleic Acid Synthesis Inhibitors
8.4. Protein Synthesis Inhibitors
9. Anti-infectives Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Topical
10. Anti-infectives Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Homecare
10.4. Hospitals
11. Americas Anti-infectives Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Anti-infectives Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Anti-infectives Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ANTI-INFECTIVES MARKET RESEARCH PROCESS
FIGURE 2. ANTI-INFECTIVES MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ANTI-INFECTIVES MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. ANTI-INFECTIVES MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTI-INFECTIVES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTI-INFECTIVES MARKET DYNAMICS
TABLE 7. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL LIQUIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VIRAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ASPERGILLUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CANDIDA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MALARIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CELL WALL SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEIC ACID SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEIN SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. CANADA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 89. CANADA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 90. CANADA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 91. CANADA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 92. CANADA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 93. CANADA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 94. CANADA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 95. CANADA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 96. CANADA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 97. CANADA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 98. CANADA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. CANADA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. MEXICO ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 101. MEXICO ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 104. MEXICO ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 105. MEXICO ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 109. MEXICO ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 110. MEXICO ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. MEXICO ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 138. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 139. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. CHINA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 151. CHINA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 152. CHINA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 153. CHINA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 154. CHINA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 155. CHINA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 156. CHINA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 157. CHINA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 158. CHINA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 159. CHINA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 160. CHINA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. CHINA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. INDIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 163. INDIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 164. INDIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 165. INDIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 166. INDIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 167. INDIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 168. INDIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 169. INDIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 170. INDIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 171. INDIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 172. INDIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. INDIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 175. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 176. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 177. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 178. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 179. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 182. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 184. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. JAPAN ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 187. JAPAN ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 188. JAPAN ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 189. JAPAN ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 190. JAPAN ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 191. JAPAN ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 192. JAPAN ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 193. JAPAN ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 194. JAPAN ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 195. JAPAN ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 196. JAPAN ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. JAPAN ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 199. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 200. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 201. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 202. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 203. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 208. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 214. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 220. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 223. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 224. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 225. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 226. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 227. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 232. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 244. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 247. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 248. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 249. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 250. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 251. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 254. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 256. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. THAILAND ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 259. THAILAND ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 260. THAILAND ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 261. THAILAND ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 262. THAILAND ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 263. THAILAND ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 264. THAILAND ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 265. THAILAND ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 266. THAILAND ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 267. THAILAND ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 268. THAILAND ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. THAILAND ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 271. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 272. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 273. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 274. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 278. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 279. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 280. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 295. DENMARK ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 296. DENMARK ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 297. DENMARK ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 298. DENMARK ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 299. DENMARK ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 300. DENMARK ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 301. DENMARK ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 302. DENMARK ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 303. DENMARK ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 304. DENMARK ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 305. DENMARK ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 306. DENMARK ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. EGYPT ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 308. EGYPT ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 309. EGYPT ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 310. EGYPT ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 311. EGYPT ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 312. EGYPT ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 313. EGYPT ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 314. EGYPT ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 315. EGYPT ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 316. EGYPT ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 317. EGYPT ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 318. EGYPT ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. FINLAND ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 320. FINLAND ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 321. FINLAND ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 322. FINLAND ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 323. FINLAND ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 324. FINLAND ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 325. FINLAND ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 326. FINLAND ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 327. FINLAND ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 328. FINLAND ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 329. FINLAND ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 330. FINLAND ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 331. FRANCE ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 332. FRANCE ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 333. FRANCE ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 334. FRANCE ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 335. FRANCE ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 336. FRANCE ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 337. FRANCE ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 338. FRANCE ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 339. FRANCE ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 340. FRANCE ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 341. FRANCE ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 342. FRANCE ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 343. GERMANY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 344. GERMANY ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 345. GERMANY ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 346. GERMANY ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 347. GERMANY ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
TABLE 348. GERMANY ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 349. GERMANY ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 350. GERMANY ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 351. GERMANY ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 352. GERMANY ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 353. GERMANY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 354. GERMANY ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 355. ISRAEL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 356. ISRAEL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 357. ISRAEL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 358. ISRAEL

Companies Mentioned

The leading players in the Anti-infectives Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cubist Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 131.43 Billion
Forecasted Market Value ( USD ) by 2030 $ 178.43 Billion
Compound Annual Growth Rate5.1%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Anti-Infective Drugs- Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Anti-Infective Drugs- Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Anti-infective Agents Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028 - Product Image

Anti-infective Agents Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028

  • Report
  • 188 Pages
  • Global
From
Anti-Infectives - Global Strategic Business Report - Product Image

Anti-Infectives - Global Strategic Business Report

  • Report
  • 116 Pages
  • Global
From
Anti-infectives Market Report by Type, Route of Administration, Distribution Channel, and Region 2024-2032 - Product Image

Anti-infectives Market Report by Type, Route of Administration, Distribution Channel, and Region 2024-2032

  • Report
  • 137 Pages
  • Global
From
Anti-infective Endotracheal Tube Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Anti-infective Endotracheal Tube Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 87 Pages
  • Global
From

About the Infection Drug Market

The Infectious Diseases Drugs market is a subset of the pharmaceutical industry that focuses on the development and production of drugs used to treat infectious diseases. These drugs are used to treat a wide range of infections, including bacterial, viral, fungal, and parasitic infections. The market is highly competitive, with many companies vying for market share. Companies in the market are typically focused on developing new drugs, as well as improving existing treatments. Additionally, many companies are involved in the production of generic drugs, which are often cheaper than brand-name drugs. Companies in the Infectious Diseases Drugs market include Pfizer, Merck, GlaxoSmithKline, Sanofi, AstraZeneca, Novartis, Johnson & Johnson, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.